We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+14.55%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
-$24.6M
Cap. Flow
-$44M
Cap. Flow %
-4.18%
Top 10 Hldgs %
44.97%
Holding
105
New
25
Increased
29
Reduced
11
Closed
33

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$33.2M
2
BDX icon
Becton Dickinson
BDX
+$17.7M
3
ELV icon
Elevance Health
ELV
+$15.9M
4
TMO icon
Thermo Fisher Scientific
TMO
+$14.3M
5
DGX icon
Quest Diagnostics
DGX
+$13.7M

Top Sells

Rank Stock Value
1
WBA
Walgreens Boots Alliance
WBA
+$28.2M
2
ABBV icon
AbbVie
ABBV
+$24.6M
3
CRL icon
Charles River Laboratories
CRL
+$17.6M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.4M
5
ISRG icon
Intuitive Surgical
ISRG
+$15.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VKTX icon
26
CALL
Viking Therapeutics
VKTX
$4.02B
$13.3M 1.26%
+250,000
New +$16.4M
VKTX icon
27
Viking Therapeutics
VKTX
$4.02B
$13.3M 1.26%
250,000
-200,000
-44% -$13.1M
RVMD icon
28
Revolution Medicines
RVMD
$44.4B
$12.6M 1.2%
325,000
-95,000
-23% -$3.55M
AMGN icon
29
Amgen
AMGN
$226B
$12.5M 1.19%
+40,000
New +$11.8M
IONS icon
30
Ionis Pharmaceuticals
IONS
$9.46B
$11.9M 1.13%
+250,000
New +$10.3M
MCK icon
31
McKesson
MCK
$103B
$11.7M 1.11%
+20,000
New +$11.1M
RGNX icon
32
Regenxbio
RGNX
$688M
$11.1M 1.06%
950,000
+190,000
+25% +$2.96M
TARS icon
33
PUT
Tarsus Pharmaceuticals
TARS
$2.97B
$10.9M 1.03%
+400,000
New +$13.4M
ITCI
34
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.93M 0.94%
145,000
+20,000
+16% +$1.39M
SNY icon
35
Sanofi
SNY
$104B
$9.7M 0.92%
+200,000
New +$9.65M
MLTX icon
36
MoonLake Immunotherapeutics
MLTX
$1.47B
$9.67M 0.92%
220,000
– –
NBIX icon
37
Neurocrine Biosciences
NBIX
$16.8B
$9.64M 0.92%
70,000
-80,000
-53% -$11M
TFX icon
38
Teleflex
TFX
$5.89B
$9.46M 0.9%
+45,000
New +$9.43M
LLY icon
39
Eli Lilly
LLY
$1.1T
$9.05M 0.86%
10,000
-2,000
-17% -$1.6M
GMED icon
40
Globus Medical
GMED
$11.6B
$8.56M 0.81%
+125,000
New +$7.47M
BRKR icon
41
Bruker
BRKR
$8.58B
$8.3M 0.79%
130,000
-90,000
-41% -$6.78M
CRSP icon
42
CRISPR Therapeutics
CRSP
$5.17B
$8.1M 0.77%
150,000
-70,000
-32% -$4.05M
OSCR icon
43
Oscar Health
OSCR
$8.54B
$7.91M 0.75%
500,000
– –
RGEN icon
44
Repligen
RGEN
$9.21B
$7.56M 0.72%
60,000
+10,000
+20% +$1.57M
DNLI icon
45
Denali Therapeutics
DNLI
$4B
$7.55M 0.72%
+325,000
New +$6.24M
TNYA icon
46
Tenaya Therapeutics
TNYA
$165M
$7.21M 0.68%
2,325,000
+75,000
+3% +$310K
SANA icon
47
Sana Biotechnology
SANA
$1B
$6.55M 0.62%
1,200,000
+220,000
+22% +$1.75M
ELAN icon
48
Elanco Animal Health
ELAN
$11.1B
$6.49M 0.62%
450,000
-100,000
-18% -$1.6M
MREO
49
Mereo BioPharma
MREO
$43.5M
$6.39M 0.61%
1,775,000
+825,000
+87% +$2.67M
MRUS
50
DELISTED
Merus
MRUS
$5.92M 0.56%
100,000
-65,000
-39% -$3.15M
1
2
3 4 5

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Integral Health Asset Management held 105 positions worth $1.05B, down 2.3% from $1.08B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Integral Health Asset Management withdrew a net $44M in Q2 2024, closing 33 positions and reducing 11 holdings. Its most notable exit was Walgreens Boots Alliance, an estimated $28.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier.

Against the trend, Integral Health Asset Management opened a new position in Becton Dickinson worth $17.5M.

  • Integral Health Asset Management's largest Q2 2024 buy was Becton Dickinson: 75,000 shares worth $17.5M.
  • Integral Health Asset Management added most to Cytokinetics in Q2 2024, an estimated $33.2M increase.
  • Integral Health Asset Management's biggest Q2 2024 reduction was Intuitive Surgical, cutting an estimated $15.9M.
  • Integral Health Asset Management fully exited Walgreens Boots Alliance in Q2 2024, selling an estimated $28.2M.
  • Integral Health Asset Management's ten largest holdings make up 45% of its $1.05B portfolio in Q2 2024.
  • Integral Health Asset Management opened 25 new positions and closed 33 in Q2 2024.
  • Integral Health Asset Management's portfolio value fell 2.3% quarter-over-quarter to $1.05B.

Based on Integral Health Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.